BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data

Morgan Stanley has revised its forecast for a Federal Reserve interest rate cut in December, now predicting a reduction of 25 basis points, a shift from its previous expectations. This change follows the release of strong jobs data, prompting the firm to reassess its earlier stance on monetary policy.

Goldman Sachs Group Inc. and Morgan Stanley have enhanced the terms of a debt offering for Sevita Whole Health LLC after initial difficulties in selling a loan for the healthcare services firm. This adjustment reflects the banks' efforts to secure financing in a challenging market environment.

Morgan Stanley has lowered its stock price target for Torrid to $1.01, citing ongoing product issues that have negatively impacted the company's performance. This adjustment reflects a broader concern regarding Torrid's ability to navigate challenges in the retail market, particularly in light of a recent sales decline reported in its Q3 2025 earnings call.

Morgan Stanley has indicated that there is potential for further increases in natural gas prices, reflecting a positive outlook for the commodity in the current market environment. This assessment comes amid various economic factors influencing energy markets.

Morgan Stanley has observed an increase in short positions on the Japanese yen, driven by expectations surrounding the fiscal policies of Minister Sanae Takaichi. This trend reflects market sentiment as investors react to anticipated changes in Japan's economic strategy.

Morgan Stanley has revised its price target for Nvidia stock from $250 to $235, indicating a potential upside of 38% from its current price of $181.46. This adjustment reflects the firm's confidence in Nvidia's continued growth in the AI sector, which has been a significant driver of its stock performance.